CN105980372B - 官能化的苯并吡喃化合物及其用途 - Google Patents

官能化的苯并吡喃化合物及其用途 Download PDF

Info

Publication number
CN105980372B
CN105980372B CN201580002687.5A CN201580002687A CN105980372B CN 105980372 B CN105980372 B CN 105980372B CN 201580002687 A CN201580002687 A CN 201580002687A CN 105980372 B CN105980372 B CN 105980372B
Authority
CN
China
Prior art keywords
cancer
compound
compounds
formula
300mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580002687.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105980372A (zh
Inventor
A·西顿
D·布朗
G·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivetho Co Ltd Publicly Listed
Original Assignee
Novogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Ltd filed Critical Novogen Ltd
Priority to CN201810378034.2A priority Critical patent/CN108484559A/zh
Publication of CN105980372A publication Critical patent/CN105980372A/zh
Application granted granted Critical
Publication of CN105980372B publication Critical patent/CN105980372B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580002687.5A 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途 Active CN105980372B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810378034.2A CN108484559A (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937368P 2014-02-07 2014-02-07
US61/937,368 2014-02-07
US201461987323P 2014-05-01 2014-05-01
US61/987,323 2014-05-01
PCT/AU2015/050040 WO2015117202A1 (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810378034.2A Division CN108484559A (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途

Publications (2)

Publication Number Publication Date
CN105980372A CN105980372A (zh) 2016-09-28
CN105980372B true CN105980372B (zh) 2018-05-08

Family

ID=53777071

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810378034.2A Pending CN108484559A (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途
CN201580002687.5A Active CN105980372B (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810378034.2A Pending CN108484559A (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途

Country Status (24)

Country Link
US (2) US9701655B2 (enExample)
EP (1) EP2953938B1 (enExample)
JP (1) JP6570042B2 (enExample)
KR (1) KR102395543B1 (enExample)
CN (2) CN108484559A (enExample)
AU (1) AU2015213484B2 (enExample)
BR (1) BR112016018099B8 (enExample)
CA (1) CA2936012C (enExample)
CL (1) CL2016001937A1 (enExample)
DK (1) DK2953938T3 (enExample)
ES (1) ES2643407T3 (enExample)
IL (1) IL241515B (enExample)
LT (1) LT2953938T (enExample)
MX (1) MX368063B (enExample)
MY (1) MY195739A (enExample)
NZ (1) NZ711603A (enExample)
PH (1) PH12016501422B1 (enExample)
PL (1) PL2953938T3 (enExample)
PT (1) PT2953938T (enExample)
RU (1) RU2676766C2 (enExample)
SA (1) SA516371583B1 (enExample)
SG (2) SG11201506988TA (enExample)
SI (1) SI2953938T1 (enExample)
WO (1) WO2015117202A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY195739A (en) * 2014-02-07 2023-02-08 Novogen ltd Functionalised Benzopyran Compounds and use Thereof
EP3253208B1 (en) 2015-02-02 2021-05-05 MEI Pharma, Inc. Combination therapies for use in the treatment of breast cancer
US10265294B2 (en) 2016-03-31 2019-04-23 Yale University Compositions and methods for treating epithelial cancer
CA3058492A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
WO2017173498A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
CN109730996B (zh) * 2017-03-01 2021-08-24 浙江大学 喹啉结构类型雄激素受体拮抗剂及其应用
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CA3181730A1 (en) * 2020-06-11 2021-12-16 Daniel P. Gold Combination therapies
WO2023235929A1 (en) * 2022-06-08 2023-12-14 Noxopharm Limited Functionalised benzopyran compounds and uses thereof
CN118005594B (zh) * 2023-05-24 2024-10-29 内蒙古大学 3-羟基苯并二氢吡喃衍生物的合成及其抗肿瘤活性

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094844A (zh) * 2004-09-21 2007-12-26 诺沃根研究控股有限公司 苯并二氢吡喃衍生物，药物及其在治疗中的应用
CN101123958A (zh) * 2003-11-19 2008-02-13 诺沃根研究股份有限公司 联合放射疗法与化学疗法的组合物和方法
WO2012061409A1 (en) * 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
BE891562A (fr) 1981-12-21 1982-04-16 Council Scient Ind Res Isomeres 1 et d de d1-3, 4-trans-3, 4-diarylchromanes 2, 2-disubstitues et leurs derives, leur preparation et leur utilisation
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
CZ212397A3 (en) 1995-01-13 1997-11-12 Novo Nordisk As Use of 3,4-diphenylchromans for preparing pharmaceutical preparations for treating or prophylaxis of hyperlipoproteinaemia, hypertriacylglycerolaemia, hyperlipidaemia, hypercholesterolaemia, arteriosclerosis and reduction of blood sedimentation
CA2208868A1 (en) 1995-01-13 1996-07-18 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
JPH10513154A (ja) 1995-01-20 1998-12-15 ノボ ノルディスク アクティーゼルスカブ 血管拡張治療または予防用の医薬組成物の製造への３，４−ジフェニルクロマンの使用
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
CZ212097A3 (en) 1995-01-20 1997-11-12 Novo Nordisk As Use of 3,4-diphenylchromans for preparing a medicament intended for treating or prophylaxis of cerebral degenerative diseases
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
JP2000506505A (ja) 1996-01-11 2000-05-30 ノボ ノルディスク アクティーゼルスカブ 閉経期の症状の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
CN1207038A (zh) 1996-01-11 1999-02-03 诺沃挪第克公司 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA979642B (en) 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
US5925771A (en) 1996-10-28 1999-07-20 Novo Nordisk A/S Process for the preparation of (-)-3,4-trans-diarylchromans
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129625A0 (en) 1996-10-28 2000-02-29 Novo Nordisk As Novel (-)-enantionmers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU5550398A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor inhibiting senescence-associated motor impairment
AU5550298A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women
US6184005B1 (en) 1998-04-28 2001-02-06 Novo Nordisk A/S Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
CN1318413C (zh) * 1998-09-23 2007-05-30 研究发展基金会 生育酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途
WO2001007031A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
WO2002030407A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
US20050119301A1 (en) 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
WO2002074307A1 (en) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
US20060141591A1 (en) 2003-06-04 2006-06-29 Youichi Kyuuko Method for producing optically active chroman-carboxylate
ATE532777T1 (de) 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP2436680B1 (en) * 2004-09-21 2016-05-18 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
ES2377073T3 (es) * 2004-09-21 2012-03-22 Marshall Edwards, Inc. Derivados de cromano sustituidos, medicamentos y utilización en terapia
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
EP1991220A1 (en) 2006-02-21 2008-11-19 Trigen Limited Heterocyclic compounds and their use in the treatment of cardiovascular disease
US20100152284A1 (en) 2006-10-30 2010-06-17 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CN101210012B (zh) 2006-12-31 2011-09-14 南华大学 新的含烟酸异黄酮酯衍生物及其制造方法和用途
EP2334296A4 (en) 2008-08-29 2012-04-25 Novogen Res Pty Ltd IMMUNOMODULATING ACTIVITIES
EP2362773A4 (en) 2008-10-22 2012-05-09 Novogen Res Pty Ltd METHOD FOR TRIGGERING PROGRAMMED CELL DEATH
AU2008230055A1 (en) 2008-10-22 2010-05-06 Novogen Research Pty Ltd Methods for Inducing Programmed Cell Death
EP2548017A2 (en) 2010-03-15 2013-01-23 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
CN102153535A (zh) 2011-03-04 2011-08-17 中国海洋大学 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用
WO2013026942A1 (en) * 2011-08-25 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Tubulin binding agents
CA2875964C (en) 2012-06-07 2018-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
CN103408528B (zh) 2013-08-13 2015-04-29 浙江大学 一种色满化合物及其制备方法和应用
CN103450142B (zh) 2013-09-04 2015-03-25 浙江大学 一种色满化合物及其提取方法和应用
CN103585145A (zh) 2013-11-28 2014-02-19 常州科立信医疗器械有限公司 Artoxanthochromane在治疗前列腺癌药物中的应用
CN103690525A (zh) 2013-12-02 2014-04-02 常州科立信医疗器械有限公司 Artoxanthochromane在治疗舌癌药物中的应用
CN103638008B (zh) 2013-12-02 2015-09-16 刘艳娇 Artoxanthochromane在治疗皮肤癌药物中的应用
CN103705503A (zh) 2013-12-04 2014-04-09 常州科立信医疗器械有限公司 Artoxanthochromane在治疗乳腺癌药物中的应用
MY195739A (en) * 2014-02-07 2023-02-08 Novogen ltd Functionalised Benzopyran Compounds and use Thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123958A (zh) * 2003-11-19 2008-02-13 诺沃根研究股份有限公司 联合放射疗法与化学疗法的组合物和方法
CN101094844A (zh) * 2004-09-21 2007-12-26 诺沃根研究控股有限公司 苯并二氢吡喃衍生物，药物及其在治疗中的应用
WO2012061409A1 (en) * 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids

Also Published As

Publication number Publication date
PL2953938T3 (pl) 2017-12-29
PH12016501422B1 (en) 2022-02-16
PH12016501422A1 (en) 2016-08-31
BR112016018099B8 (pt) 2023-01-17
MX2016010137A (es) 2017-02-15
AU2015213484A1 (en) 2015-09-17
CA2936012C (en) 2023-03-07
CL2016001937A1 (es) 2017-01-20
CN105980372A (zh) 2016-09-28
EP2953938B1 (en) 2017-08-02
LT2953938T (lt) 2017-10-10
BR112016018099B1 (pt) 2022-10-11
PT2953938T (pt) 2017-10-09
NZ711603A (en) 2017-05-26
US9701655B2 (en) 2017-07-11
IL241515B (en) 2019-06-30
US10370349B2 (en) 2019-08-06
WO2015117202A1 (en) 2015-08-13
SG11201604490SA (en) 2016-07-28
KR102395543B1 (ko) 2022-05-09
EP2953938A4 (en) 2016-08-10
DK2953938T3 (en) 2017-10-02
BR112016018099A2 (pt) 2017-08-08
US20160340329A1 (en) 2016-11-24
JP2017507175A (ja) 2017-03-16
JP6570042B2 (ja) 2019-09-04
CA2936012A1 (en) 2015-08-13
US20180141925A1 (en) 2018-05-24
SI2953938T1 (en) 2018-01-31
IL241515A0 (en) 2015-11-30
RU2016133731A (ru) 2018-03-12
HK1218914A1 (en) 2017-03-17
RU2676766C2 (ru) 2019-01-11
CN108484559A (zh) 2018-09-04
MX368063B (es) 2019-09-18
ES2643407T3 (es) 2017-11-22
EP2953938A1 (en) 2015-12-16
SA516371583B1 (ar) 2019-04-18
RU2016133731A3 (enExample) 2018-08-08
AU2015213484B2 (en) 2015-11-05
SG11201506988TA (en) 2015-10-29
MY195739A (en) 2023-02-08
KR20160110427A (ko) 2016-09-21

Similar Documents

Publication Publication Date Title
CN105980372B (zh) 官能化的苯并吡喃化合物及其用途
JP6666494B2 (ja) がんの処置のための医薬の組合せ
PL199781B1 (pl) Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
JP2016530285A (ja) 癌の撮像及び治療のためのハロゲン化化合物、及びその使用方法
JP2021508318A (ja) チューブリン阻害剤
JP7181565B2 (ja) Ｙａｐ－ｔｅａｄ結合を阻害する化合物、およびそれを有効成分として含有する癌の予防または治療用医薬組成物
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
WO2012022780A1 (en) 18-beta-glycyrrhetinic acid derivatives with anti-tumor activity
CA2868120C (en) Kinase inhibitors for the treatment of cancer
CN103130632B (zh) 1-取代苯亚甲基-2-萘酮类衍生物及制备方法和用途
CA3017557A1 (en) Combination therapy for proliferative diseases
HK1263249A1 (en) Functionalised benzopyran compounds and use thereof
HK1218914B (en) Functionalised benzopyran compounds and use thereof
WO2020261242A1 (en) Chromene-based compounds, methods and uses thereof
AU2015201006A1 (en) Benzopyran compounds and use thereof
TWI723030B (zh) 二氫異丹蔘酮ｉ於治療癌症之用途
CN114051408A (zh) 用于预防、改善、或治疗癌症的组合物
KR20100004681A (ko) ｐ21의 발현을 증가시키는 활성을 갖는 화합물5,4'-디메톡시플라본의 항암제로서의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: New South Wales Australia

Applicant after: NOVOGEN LTD.

Address before: New South Wales Australia

Applicant before: NOVOGEN LTD.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250908

Address after: Solna, Sweden

Patentee after: Vivetho Co., Ltd. (Publicly Listed)

Country or region after: Sweden

Address before: New South Wales Australia

Patentee before: NOVOGEN LTD.

Country or region before: Australia